Evidence map›Paper›PMID 37705835›Full record

ArticleThe British journal of cardiology2023

Cardiac sarcoidosis: the role of cardiac MRI and

Muntasir Abo Al Hayja, Sobhan Vinjamuri

Abstract read
In one paragraph

Article in The British journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Beyond the Biopsy: Imaging Frontiers in Cardiac Sarcoidosis.Cardiology research and practice · 2026
    Review
  3. Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  4. Review
  5. Review
  6. Cardiac sarcoidosis: diagnosis and management.Frontiers in cardiovascular medicine · 2024
    Review
  7. Exploring the latest advances inAmerican journal of nuclear medicine and molecular imaging · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muntasir Abo Al HayjaConsultant Cardiologist - Cardiac Imaging Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP.
Sobhan VinjamuriProfessor and Lead Consultant in Nuclear Medicine Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a multi-factorial inflammatory disease characterised by the formation of non-caseating granulomas in the affected organs. Cardiac involvement can be the first, and occasionally the only, manifestation of sarcoidosis. The prevalence of cardiac sarcoidosis (CS) is higher than previously suspected. CS is associated with increased morbidity and mortality. Thus, early diagnosis is critical to introducing immunosuppressive therapy that could prevent an adverse outcome. Endomyocardial biopsy (EMB) has limited utility in the diagnostic pathway of patients with suspected CS. As a result, advanced imaging modalities, i.e. cardiac magnetic resonance imaging (MRI) and positron emission tomography with

Indexed as

cardiac magnetic resonance imagingcardiac sarcoidosiscomputed tomography (CT)late gadolinium enhancementpositron emission tomography (PET)

Identifiers

PMID37705835
PMCPMC10495763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.